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Purpose: To evaluate the short-term effect of lamivudine (LMV) treatment for severe chronic hepatitis B.
Method: Patient data related to the safety and efficacy of using lamivudine (LMV) to treat hepatitis B virus
(HBV)-induced liver failure or severe hepatitis were acquired from previous literature. These studies were retrieved
from PubMed, Ovid, SpringerLink, Biosis Previews, Academic Search Premier, ProQuest Medical Library, Cochrane
Library, China National Knowledge Infrastructure Full-text Database, VIP Chinese Scientific Journal Database, and
Chinese Biomedicine. Relative risk and weighted mean difference were used to measure the effects. The major
predictors observed included total bilirubin (TBIL), prothrombin activity (PTA), survival rate, and HBV-DNA negative
change rate. Groups were further divided according to the clinical course and disease staging.
Results: A total of 242 studies were retrieved from the databases. At weeks 4, 8, and 12 of the treatment course,
the survival rates and PTA of the test group were distinctively higher than those of the control group. However,
TBIL concentrations in the test group were lower than the control group. The HBV-DNA negative change rate was
distinctively higher throughout the 12 weeks of LMV treatment. For patients who started LMV treatment in the
middle stage, the mortality rate of the test group was lower. For patients who started LMV treatment during the
advanced stage, no significant difference was observed between the test and control groups.
Conclusion: LMV decreased HBV-DNA levels in the serum, improved liver function in patients, and enhanced
survival rate during the early and medium stages of severe chronic hepatitis B.
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Severe hepatitis is a syndrome characterized by liver fail-
ure due to the death or severe degeneration of a large
number of liver cells. This severe, progressive, and com-
plex syndrome frequently results in multiple organ fail-
ure. Severe hepatitis has a mortality rate of over 70%
[1-3]. Various hepatitis virus types can lead to severe
hepatitis. In China, hepatitis B virus (HBV) infection is
the leading cause of severe hepatitis [4]. One of the im-
portant mechanisms of severe hepatitis is the high level of
HBV replication and protein antigen expression on target* Correspondence: linzhangcn@yeah.net
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reproduction in any medium, provided the orcell surfaces, which often leads to cytotoxic T lymphocyte
(CTL)-mediated immune response. This mechanism
causes death to large numbers of liver cells [5-7]. Re-
searchers have hypothesized that liver cell damage
could be controlled by inhibiting HBV replication to
inhibit immune responses [8]. No safe and effective
drug for severe hepatitis B existed before nucleoside ana-
logs were used as alternative options. Current treatments
for severe hepatitis include supportive and symptomatic
treatment-based comprehensive treatment, artificial liver
support systematic treatment, and liver transplant [9].
With the increasing development and clinical use of nu-
cleoside analog drugs, an increasing number of studies
have also been conducted. However, these studies have
not reached a consensus. Several studies have indicated
that these drugs help lower the mortality rate andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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also suggest that nucleoside analog drugs have been inef-
fective. In addition, other studies have reported that the
increase of liver failure cases is attributed to lamivudine
(LMV) use. Nevertheless, the adverse effect of LMV on
patients with hepatic insufficiency is still unclear. There-
fore, HBV-related liver failure cannot be listed as the indi-
cation for LMV.
In “AASLD Position Paper: The Management of
Acute Hepatitis,” “Guidelines for the Diagnosis and
Treatment of Liver Failure,” and “Chronic and Acute
Liver Failure Consensus” released by the Asia-Pacific
Liver Disease Association, nucleoside analog drugs were
recommended as antivirus treatment. However, the
level of evidence is only Grade 3 (experience and com-
ments by specialists or authority). In the present study,
studies published before December 2010 were reviewed
to evaluate the outcome of the LMV treatment for
HBV-related liver failure using evidence-based perspec-
tives. A meta-analysis was conducted to evaluate the
efficacy of LMV in treating severe chronic hepatitis B.
Materials and methods
Literature search strategy
The data base for our research include PubMed, Ovid,
SpringerLink, Biosis Previews, Academic Search Prem-
ier, ProQuest Medical Library, Cochrane Library, China
National Knowledge Infrastructure Full-text Database,
VIP Chinese Scientific Journal Database, and Chinese
Biomedicine. The timeframe for literature search is
from the establishment dates of these databases until
December 2010. The subject term included “hepatic
failure” OR “liver failure” OR “severe hepatitis B” OR
“hepatitis B virus” OR “HBV”, AND “lamivudine” AND
“RCT” OR “CCT” OR “cohort study”. And absence of
any language restrictions.
Inclusion and exclusion criteria
The following were the inclusion criteria:
(1) Research object: severe chronic hepatitis B,
consistency of diagnosis and staging with the
diagnosis criteria proposed by “Prevention and
treatment scheme for virus-related hepatitis” [10],
released in 2000, or “Guidelines for the diagnosis
and treatment of liver failure,” released in 2006;
(2) HBV-DNA>103 copies/ml;
(3) Interventional measure: routine comprehensive
treatment in the control group; LMV (100 mg/d)
combined with routine comprehensive treatment
in the test group;
(4) The neutrality and comparability of the two groups
studied in terms of age, gender, and other
biological or chemical predictors; and(5) Published status and full text availability of the
studies considered.
The following were the exclusion criteria:
(1) Reports involving concurrent infection with
hepatitis A, C, D, and E virus, Epstein-Barr virus,
cytomegalovirus, HIV, and others;
(2) Reports involving concurrence with drug-induced
liver injury, auto-immune liver disease, alcoholic
liver disease, and inherited metabolic disease,
among others.
(3) Reports involving concurrence with malignant
tumors and severe blood anomalies.
(4) Reports covering only adverse effects or descriptive
studies;
(5) Non-convertible or unusable data in literature;
(6) Reports involving comparisons or use of LMV with
Chinese medicine; and
(7) Reports involving concurrence with plasma
exchange treatment.
Indicators of therapeutic efficacy
Survival, total bilirubin (TBIL), prothrombin activity
(PTA), and HBV-DNA negative change rates were com-
pared between the test and control groups at weeks 4, 8,
and 12. These rates were considered indicators for
evaluating LMV efficacy. The effects of starting LMV
treatment at different time points during the clinical
course of liver failure were also observed.
Quality evaluation and information collection
At least two evaluators were involved in the selection of
studies to conduct quality evaluations and information
collection independently before exchanging evaluation re-
sults with one another. In cases of disagreement, a third
evaluator settled the dispute. The quality evaluation for
RCT was conducted according to the Jadad measuring
scale [11], whereas that for CCT was conducted according
to the Stroup criteria [12].
The information collected included basic information
on the studies, sample sizes, intervention characteristics
(intervention measures, dosage, course, follow-up, etc.),
receiver characteristics (gender, age, TBIL, PTA, virus
infection, complication, etc.), and results.
Statistical analysis
Revman 4.2 was used for statistical analysis. Among the
indicators compared, relative risk (RR) and 95% confi-
dence interval (95% CI) were used to compare the mor-
tality, survival, and HBV-DNA negative change rates.
Weighted mean difference (WMD) and 95% CI were
used to compare TBIL and PTA. Based on the sugges-
tion of the Journal of American Medical Association
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the heterogeneity of the data collected. A fixed model
was used in meta-analysis. A P value greater than 0.05
indicated no statistical heterogeneity, whereas a P value
less than 0.05 indicated statistical heterogeneity. Sub-
group and sensitivity analyses were used to exclude the
suspected cause for clinical and statistical heterogeneity.
If heterogeneity still existed, the random effect model
was used in meta-analysis. A funnel chart was used to
detect possible publication biases. Results were further
tested by sensitivity analysis.Results
Inclusion of basic information on studies retrieved
A total of 242 relevant studies (97 in English, 145 in
Chinese) were retrieved from the databases, and 21
were ultimately included after literature screening. Of
the 21 studies included, 13 were RCT and 8 were cohort
studies. A total of 780 cases were included in the test
group, whereas 768 cases were included in the control
group. The process of selecting comparative studies in-
cluded in our meta-analysis was shown in Figure 1. TheFigure 1 Flow diagramme.characteristics and quality assessments of included
studies are shown in Table 1.
Literature quality
As shown in Figure 2, the funnel plot, which indicates
the effect size measures of the studies included, was
symmetrically scattered on both sides of the real value.
Thus, publication bias was unlikely. A sensitivity test
was performed to test the reliability of meta-analysis.
Studies with treatments that varied largely from the real
value were excluded. After the sensitivity test, the
remaining studies were subjected to another test. No in-
dication of publication bias was found.
Effect of LMV treatment on the survival rate
Survival rate was considered predictive of prognosis in
16 of the studies included [14-19,22-25,27,28,30,32-34]
with 638 cases in the test group and 600 cases in the
control group. In the heterogeneity test, χ2=60.06, df=17,
and P<0.00001, suggesting a certain degree of heterogen-
eity among the included studies. Therefore, the random
effect model was used to combine the effect measures
using RR as indicator (RR=1.22), and 95% CI was (1.13,
Table 1 Characteristics of studies included in the meta-analysis
Study Year Country Group n M/F Age (yr) (mean ± SD)
Sun LJ et al. [14] 2009 China Test 130 104/26 N/A
Cont. 130 104/26 N/A
Cui YL et al. [15] 2010 China Test 34 3/31 39.35 ± 10.61
Cont. 37 6/31 41.03 ± 11.48
Mi Lj et al. [16] 2009 China Test 30 30/712 38.4 ± 2.5
Cont. 28 24/3 38.3 ± 2.4
Zhang P [17] 2008 China Test 48 38/10 47 ± 15.8
Cont. 44 36/8 48 ± 16.2
Han YH et al. [18] 2007 China Test 58 36/22 N/A
Cont. 48 29/19 N/A
Yang DH et al. [19] 2004 China Test 30 N/A N/A
Cont. 41 N/A N/A
He Y et al. [20] 2005 China Test 13 11/2 38.2
Cont. 24 21/3 37.8
Liao JH et al. [21] 2004 China Test 36 29/7 39.5 ± 17.6
Cont. 40 32/8 38.6 ± 16.8
Yuan J et al. [22] 2001 China Test 20 17/3 35.1 ± 11.6
Cont. 20 20/0 34.8 ± 8.5
Zhang LQ et al. [23] 2006 China Test 29 24/5 N/A
Cont. 20 18/2 N/A
Zhan GQ et al. [24] 2006 China Test 62 N/A N/A
Cont. 36 N/A N/A
Cao L et al.[25] 2007 China Test 45 N/A N/A
Cont. 46 N/A N/A
Zhu GL et al. [26] 2002 China Test 31 25/6 N/A
Cont. 31 23/8 N/A
Zhou BX et al. [27] 2011 China Test 21 16/5 37.2
Cont. 21 15/6 38.1
Guo JC et al. [28] 2002 China Test 24 24/0 38 ± 17.1
Cont. 24 24/0 39 ± 18.4
Zhong YB et al. [29] 2007 China Test 24 20/4 29.2 ± 16.8
Cont. 35 29/6 33.8 ± 18.7
Zhou XX et al. [30] 2007 China Test 17 14/3 N/A
Cont. 18 15/3 N/A
Ding FY et al. [31] 2003 China Test 38 31/7 N/A
Cont. 38 33/5 N/A
Pan JZ et al. [32] 2007 China Test 40 N/A N/A
Cont. 42 N/A N/A
Wang Y et al. [33] 2003 China Test 30 N/A N/A
Cont. 30 N/A N/A
Qin SJ et al. [34] 2003 China Test 20 N/A N/A
Cont. 15 N/A N/A
Zhang et al. Virology Journal 2013, 10:134 Page 4 of 12
http://www.virologyj.com/content/10/1/134
Figure 2 Funnel plot for publication bias analysis.
Figure 3 Effect of LMV treatment on the survival rate.
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http://www.virologyj.com/content/10/1/1341.32). In the forest plot, the diamond was completely on
the right side of the vertical line. In the test for the overall
effect, Z=5.11 and P<0.00001, suggesting that LMV treat-
ment in patients with severe chronic hepatitis B improved
survival rate. A significant statistical difference between
the test and control groups was observed. Heterogeneity
in the subgroup analysis was confirmed during the treat-
ment course (weeks 4, 8, and 12). Therefore, the random
effect model was used for the subgroup analyses. The RRs
were 1.37, 1.29, and 1.24, respectively, and the 95% CIs
were (1.18, 1.60), (1.04, 1.6), and (1.03, 1.26), respectively.
In the test for the overall effect, P < 0.05, indicating a sig-
nificant statistical difference. Thus, LMV improves the
survival rate of patients at weeks 4, 8, and 12 during the
treatment course (Figure 3).
TBIL comparison between test and control groups
TBIL was considered predictive for prognosis in 18 of
the included studies [16-29,31-34], with 599 cases in the
test group and 583 cases in the control group. In the
heterogeneity test, χ2=211.61, df=21, and P<0.00001,
suggesting a certain size of heterogeneity among the in-
cluded studies. Therefore, the random effect model was
used to combine the effect measure using WMD as theFigure 4 Effect of LMV treatment on TBIL.indicator (WMD=131.1), and 95% CI was (97.56, 164.65).
In the forest plot, the diamond was completely on the
right side of the vertical line. In the test for the overall ef-
fect, Z=7.66, and P<0.00001. Thus, LMV decreases the
TBIL level in patients. A significant statistical difference
was observed between the test and control groups.
Heterogeneity was confirmed in the treatment course sub-
group analysis for weeks 4, 8, and 12. Therefore, the ran-
dom effect model was used for the subgroup analyses.
The overall WMDs were 146.11, 173.89, and 88.41, re-
spectively. The 95% CI were (107.42, 184.79), (87.61,
260.18), and (42.59, 134.23), respectively. In the test for
the overall effect, P < 0.05, indicating a significant differ-
ence between the test and control groups. LMV treatment
thus decreases the TBIL level at weeks 4, 8, and 12 during
the treatment course (Figure 4).
PTA comparison between test and control groups
PTA was considered the predictor for prognosis in 14 of
the included studies [18-20,22-27,29,31-34], with 461
cases in the test group and 447 cases in the control
group. In the heterogeneity test, χ2=425.49, df=13, and
P<0.00001, which suggest a certain size of heterogeneity
among the studies included. Therefore, the random
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WMD. WMD=17.19, and 95% CI was (11.56, 22.82). In
the forest plot, the diamond was completely on the right
side of the vertical line. In the test for the overall effect,
Z=5.99, and P<0.00001. LMV treatment thus increases
PTA levels in patients and improves coagulation func-
tion. A significant statistical difference was observed be-
tween the test and control groups. Heterogeneity was
confirmed in the treatment course subgroup analysis for
weeks 4, 8, and 12. Therefore, the random effect model
was used for the subgroup analyses. The overall WMD
were 11.51, 25.95, and 18.07, respectively, and overall 95% CI
were (5.75, 17.28), (15.72, 36.18), and (6.33, 29.82), respec-
tively. In the test for the overall effect, P < 0.5, indicating a
significant difference between the test and control groups.
Thus, LMV treatment increases the PTA level at weeks 4, 8,
and 12 during the treatment course (Figure 5).
Comparison of HBV-DNA negative change rate between
test group and control group
The HBV-DNA negative change rate was considered the
predictor for prognosis in six of the included studies
[18,25,27,28,31,34], with 206 cases in the test group and
192 cases in the control group. In the heterogeneity test,
χ2=3.18, df=5, and P=0.67>0.05, which suggest noFigure 5 Effect of LMV treatment on TBIL.substantial heterogeneity among the six studies. There-
fore, the fixed effect model was used to combine the ef-
fect measure, RR. RR=8.14, and 95% CI was (5.2, 12.72).
In the forest plot, the diamond was completely on the
right side of the vertical line. In the test for the overall
effect, Z=9.2, and P<0.00001. Thus, LMV treatment sig-
nificantly inhibits HBV-DNA change. The negative
change rate in the test group was 14 times higher than
that in the control group, which also signifies a statisti-
cally significant difference (Figure 6).
Effect of LMV treatment at different stages of liver failure
on the prognosis
Four of the included studies [17,18,29,32] were divided
into three stages, namely, early, medium, and advanced.
This classification was done according to “Diagnosis and
Prevention Scheme for Viral Hepatitis.” Mortality rate
was used as the indicator for prognosis.
Fifty-nine cases were included in the early stage test
group and 54 in the control group. In the heterogeneity
test, χ2=0.96, df=3, and P=0.81>0.05, which suggests no
substantial heterogeneity among the studies included.
Therefore, the fixed effect model was used to combine
the effect measure, RR. RR=0.21, 95% CI was (0.09,
0.51). In the forest plot, the diamond was completely on
Figure 6 Effect of LMV treatment on HBV-DNA negative change rate.
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effect, Z=3.46, and P=0.0005. A significant difference
was observed between the test and control groups. Thus,
LMV treatment during the early stage decreases the
mortality rate.
Seventy cases were included in the medium stage test
group and 72 in the control group. In the heterogeneity
test, χ2=2.0, df=3, and P=0.56>0.05, which suggests no
substantial heterogeneity among the studies included.
Therefore, the fixed effect model was used to combine the
effect measure, RR. RR=0.43, and 95% CI was (0.28, 0.66).
In the forest plot, the diamond was completely on the left
side of the vertical line. In the test for the overall effect,
Z=3.83, and P=0.0001. A significant difference was ob-
served between the test and control groups. Thus, LMV
treatment in the early stage decreases the mortality rate.
Forty-one cases were included in the advanced stage
test group and 35 in the control group. In the hetero-
geneity test, χ2=0.11, df=1, and P=0.73>0.05, which sug-
gests no substantial heterogeneity among the studies
included. Therefore, the fixed effect model was used to
combine the effect measure, RR. RRc=0.98, and 95% CI
was (0.79, 1.22). In the forest plot, the diamond over-
lapped with the no-effect vertical line. In the test for the
overall effect, Z=0.17, and P=0.86, suggesting no signifi-
cant difference between the test and control groups in
the advanced stage (Figure 7).
Adverse effect
No adverse effect was identified in the studies included.
Discussion
The mechanism for severe hepatitis is rather compli-
cated and remains unclear. Current understanding on
HBV-related liver failure/severe hepatitis holds that liver
tissues undergo irreparable damage from immunologic
injury, ischemia, hypoxia, and endotoxemia [35]. Amongthese conditions, HBV replication has a primary and
dominant function in the onset of these diseases [36-38].
HBV replication leads to the hyperfunction of immune
responses, especially the CTL-mediated cellular immune
response. A retrospective study on the cause and out-
come of chronic and acute liver failure conducted by
Zhao et al. [39] suggests that HBV replication and muta-
tion primarily cause severe hepatitis B. Therefore, a rea-
sonable solution for treating severe hepatitis B is to
reduce the total number of viruses within the body and
relieve immune hyperactivity using antivirus drugs.
Several studies claim LMV treatment during the early
stage and before the bilirubin level exceeds 20 mg/dl can
improve the prognosis and reduce mortality rate. How-
ever, untimely LMV treatment will lose its effectiveness
[40-42]. Thus, the key to reducing the mortality rate of
severe chronic hepatitis B is early treatment. Antivirus
treatment is especially crucial for patients confirmed for
HBV replication-associated liver damage to protect the
unaffected liver cells. A retrospective matched cohort
study by Sun et al. [14] reviewed 130 cases of severe
chronic hepatitis B patients receiving LMV treatment.
All patients were observed for 3 months of follow-up.
The test group was found to have a higher survival rate
than the control group (P=0.0021), and patients with a
larger number of viruses had a higher mortality rate.
The Cox proportional hazards model was used to evalu-
ate predictors relating to patient prognosis. Patients with
a model for end-stage liver disease (MELD) score be-
tween 20 and 30 showed a significantly lower mortality
rate if treated with LMV during the early stage. How-
ever, LMV treatment did not improve outcomes in pa-
tients with MELD scores over 30. In the report of Yu
et al. [43], the significant drop in HBV-DNA is an im-
portant predictor for the prognosis of severe chronic
hepatitis B patients with MELD scores between 30 and
40. LMV is well tolerated in all patients, suggesting
Figure 7 Effect of LMV treatment on mortality rate of patients in different stages.
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chronic hepatitis B.
However, several reports claim that antivirus treat-
ment, mostly LMV treatment, does not have good clin-
ical effects on patients with severe chronic hepatitis. B.
Yuen et al. [44] claim that even early LMV treatment
cannot improve the prognosis of patients with severe
chronic hepatitis B. In a study done by Tsubata et al.
[45], 25 patients with severe chronic hepatitis B re-
ceived regular treatment combined with LMV. Another
25 patients were placed in the control group. Six pa-
tients in the test group (24%) and seven in the control
group (28%) almost immediately underwent liver fail-
ure. Among those patients, three from the test group
and two from the control group survived. However, this
gap cannot represent a statistical difference in
supporting the efficacy of LMV in inhibiting the pro-
gress of severe chronic hepatitis B. In the research by
Cui et al. [15], 104 patients with severe chronic hepatitisB were divided into three groups, namely, the LMV,
entecavir (ETV), and routine groups. During 3 months
of follow-up observation, the survival rates for the three
groups were 48.49%, 50%, and 40.54%, respectively. No
significant difference was observed in the survival rate
(P=0.72), in liver function and kidney function, and
MELD score. However, five patients from the routine
group had a relapse. Even though LMV and ETV are not
effective in improving the prognosis of patients in the
short-run, both can help reduce the relapse rate for se-
vere chronic hepatitis B. Thus, patients may benefit
from long-term effects. Researchers also claim that the
prolonged use of LMV increases the risk of drug resist-
ance. Once tyrosine-methionine-aspartate-aspartate muta-
tion occurs, the outcome achieved is endangered and even
exacerbates patient conditions. In the research by Wong
et al. [46], 45 patients with severe chronic hepatitis B and
positive hepatitis B ‘e’ antigen (HBeAg) received LMV
treatment. The test group showed a significantly higher
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(73% vs. 52%). However, 33% of patients in the LMV
group exhibited drug resistance and relapse in 5 years,
and 73% patients suffered from exacerbated disease
conditions.
The effect of LMV on severe chronic hepatitis B induced
by HBV is still unconfirmed and is a topic of disagreement
among researchers. LMV is a type of pyrimidine nucleo-
side analog that can inhibit the activity of DNA polymer-
ase and reverse transcriptase. This inhibition decreases
HBV replication, thereby reducing the number of viruses
in the liver and blood, decreasing the target antigen ex-
pression on the surface of liver cells, and reducing CTL at-
tacks on infected liver cells. Thus, both the primary and
sustaining factors can be effectively controlled. In the
present research, CCTs conducted before December 2010
that aimed to compare the effects of LMV and routine
treatments on severe chronic hepatitis B were collected.
Through meta-analysis, LMV was found to inhibit HBV
replication. TBIL, PTA, and survival rates all showed sig-
nificant improvements. Thus, inhibiting HBV replication
can inhibit HBV replication in infected liver cells, thereby
reducing the risk of new infections. Thus, inhibiting HBV
replication relieves the inflammatory reaction in the liver,
boosts liver cell function recovery, and improves the prog-
nosis of patients.
LMV treatment during the early and medium stages
can decrease the mortality rate of patients with severe
chronic hepatitis B. However, for the advanced stage, no
significant difference was found between the test and
control groups. Antivirus treatment can prolong the
lives of patients, which provides valuable time for liver
cell reproduction. However, during the advanced stage,
patients usually suffer from significantly worse liver cell
death and are also more likely to suffer from complica-
tions, accelerating patient death. Patients can benefit
from antivirus treatment during the early and medium
stages, but a liver transplant is a more reasonable choice
for patients in the advanced stage.
Currently, the four types of nucleoside drugs available
in the Chinese market include LMV, telbivudine, ETV,
and adefovir dipivoxil. LMV, telbivudine, and ETV have
rapid curative effects with powerful antiviral capacity,
whereas adefovir dipivoxil has a slow effect and results
in the adverse reaction of increased serum creatinine.
When this reaction occurs, adefovir dipivoxil is not ap-
plicable in treating hepatic failure. Among the former
three types of nucleoside drugs, ETV can lead to lactic
acidosis in patients with severe hepatitis and cirrhosis.
Telbivudine can result in increased creatine kinase.
Therefore, neither ETV nor telbivudine are less than
LMV. Although LMV is associated with a high drug re-
sistance rate during long-term treatment, this rate does
not influence its application in treating hepatic failure.Consequent problems such as drug resistance can be
managed by follow-up monitoring.
Severe hepatitis occurs as a series of pathological and
physiological processes initiated by the primary im-
munologic injury of liver cells and prompted by massive
liver cell death. Liver cell death is caused by the
endotoxemia-induced release of cytokines and inflam-
matory mediators [47-50]. Several studies claim that se-
vere chronic hepatitis B can progress even though HBV-
DNA levels have been controlled within an undetectable
range, causing patientdeath. Thus, viral infection is not
the only factor for the progression of severe chronic
hepatitis B. Other than liver transplant, we believe that
another reasonable treatment is to give patients an early
antivirus treatment based on proactive primary care
(rest, hepatoprotective treatment, symptomatic treat-
ment, artificial liver support, etc.).
Meta-analysis is as a novel way of literature review.
Meta-analysis can comprehensively evaluate and quantita-
tively analyze multiple research results from a systematic
and objective perspective, thereby improving the efficiency
of statistical analysis and tests. Although a large number
of studies were included in the present research, analyses
were also conducted to evaluate the publication bias of
such studies. The present research is not different from
others in terms of its subjection to publication bias due to
the possibility of unpublished studies with negative results.
Furthermore, the objectiveness and accuracy of meta-
analysis largely depend on a pool of high-quality literature.
Due to the limitation of disease categories and ethical rea-
sons, large-scale, multi-centered RCTs are impractical for
studies like the present paper. Several flaws exist in the lit-
erature inclusion method. These limitations have all af-
fected the stability of research results. Therefore, the
aforementioned conclusions still await further research
with increased high-quality random controlled research
literature included.
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